Versão HTML básica
62
|
HEMO
october/november/december 2013
panorama
Pediatrics
perspectives
Even with the diagnostic and therapeutical
progress, hematological and onco-hematological
diseases and the lack of medicines supplies still
are a great chalenge to the Country
By Marina Panham
T
he announcement of suspen-
sion of the manufacturing of
L-asparaginase in the beginning
of 2013 made the Brazilian medical com-
munity to see the risk of lack of the medi-
cation and the impact that this could have
in the treatment of the patients with acute
lymphoblastic leukemia (LLA) and lym-
phoblastic lymphoma (LL) in both, Public
and Suplementar Health. Attentive to this
problem, the o
Comitê de Hematologia e
Hemoterapia Pediátrica da Associação
Brasileira de Hematologia, Hemoterapia
e Terapia Celular
(ABHH) and other
entities intervened to garantee its supply
and mainly the lifespan of the patients.
According to the pediatrician and onco-
hematologist, president of the Comitê,
Sandra Loggetto the group is checking the
situation, because L-asparaginase is the
only medicine that has results with LLA,
and to stop the therapy can damage the
patient’s prognostic. To the pediatrician
onco- hematologist and vice-president
of SOBOPE, Isis Quezado Magalhães,
the episode has mobilized actors com-
mited to the cause of children’s cancer in
the Country, mainly with leukemia. “We
explained to the
Ministério da Saúde
the
importance of the medication and the
gravity of the possibility of lack of it in the
Country”, says Isis.
To guarantee the supply of
L-asparaginase in the public realm, the
Secretaria de Ciência, Tecnologia e
Insumos Estratégicos do Ministério da
Saúde
, through the
Departamento de
Assistência Farmacêutica
(DAF), decided
to centralize the purchase of the medica-
tion and distribute them to the
Secretarias
Estaduais de Saúde
. However, the
Comitê
has questioned the policies of distribu-
tion to the Suplementar Health, that are
not well defined yet. According to the
official amendment nº 21, of August, the
26th, 2013, the patients of private ser-
vices a form of solicitation of the oncol-
ogy services registered at SUS, to obtain
L-asparaginase. Recently, the ABHH send
a document to the
Ministério da Saúde
(MS) to clarify the purchasing process to
the patients of the Suplementar Health,
and waits a response. In medium term, the
©
Shutterstock